Cambridge Enterprise, University of Cambridge
Cambridge Enterprise exists to help University of Cambridge inventors, innovators and entrepreneurs make their ideas and concepts more commercially successful for the benefit of society, the UK economy, the inventors and the University.
|Address:||Hauser Forum, 3 Charles Babbage Road, Cambridge|
|Membership type:||Cambridge University Department|
Cambridge Enterprise Limited is responsible for the commercialisation of University of Cambridge intellectual property and is a wholly owned subsidiary of the University. Activities include management and licensing of intellectual property and patents, proof of concept funding and support for University staff and research groups wishing to provide expert advice or facilities to public and private sector organisations. Cambridge Enterprise provides access to angel and early stage capital through the Cambridge Enterprise Seed Funds and Cambridge Enterprise Venture Partners, and offers business planning, mentoring and other related programmes.
The University leads the world in transformative research and Cambridge Enterprise is well placed to support the academics to find the best commercialisation route for their innovations either through licensing, company creation or consultancy. Income over the past three years exceeded £27 million, of which over £22 million was distributed to University academics and departments, with the remainder reinvested in patent assets, seed fund pools and support for knowledge and technology transfer services to the University.
The website contains information on technologies available for licensing and details of companies formed with technology arising from the University of Cambridge. Cambridge Enterprise is also responsible for the commercial licensing of research reagents owned by the University.
Dr Geraldine Rodgers, an early, driving force of University investment support for spin-out companies, has died from lung cancer. She was 66.
27 January 2015Read in full
Dr Richard Jennings, a UK pioneer in the field of academic knowledge transfer, will in March step down as Deputy Director of Cambridge Enterprise (CE), the commercialisation arm of the University of Cambridge.
21 January 2015Read in full
Fluidic Analytics Limited, a spin-out from the University of Cambridge, has raised £1.56 million (US$2.4 million) in a Series A financing led by Cambridge Enterprise and including DFJ Esprit, IQ Capital, Parkwalk Advisors and Amadeus Capital Partners as co-investors.
12 January 2015Read in full
Three University of Cambridge projects have been selected as winners in GSK’s 2014 Discovery Fast Track Challenge, which is designed to accelerate the translation of academic research into novel therapies.
1 December 2014Read in full
The US Food and Drug Administration (FDA) has approved Lemtrada(TM) (alemtuzumab) for the treatment of patients with relapsing forms of multiple sclerosis (MS), Sanofi and its subsidiary Genzyme have announced.
18 November 2014Read in full
The European Medicines Agency (EMA) has recommended granting AstraZeneca marketing authorisation for Lynparza (olaparib), a first-in-class medicine for the treatment of women with a subtype of ovarian cancer for which there are limited approved treatment options.
3 November 2014Read in full
The difficulty in translating university research into the commercial realm is a well-documented problem. The reason is often that industry and academia are driven by different motivations related to their fundamentally distinct core.
31 October 2014Read in full
Investment Associate for Cambridge Innovation Capital (CIC)
Our partner organisation is recruiting. Cambridge Innovation Capital is an investment fund that invests in high-growth techno...
Salary: £0 - £0